Molecular Determinants of Response to Neoadjuvant Pembrolizumab Plus Chemotherapy in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer: Exploratory Analysis of the Open-Label, Multicohort Phase 1b KEYNOTE-173 Study
Breast Cancer Research(2025)
Key words
Immunohistochemistry,Triple-negative breast cancer,Tumor microenvironment
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined